


## Maxacalcitol

## Chemical Properties

CAS No. :	103909-75-7
Formula:	C <sub>26</sub> H <sub>42</sub> O <sub>4</sub>
Molecular Weight:	418.61
Storage:	Store at low temperature Powder: -20°C for 3 years <i>Actual storage temperature shall be subject to the COA.</i>



## Biological Description

Description	Maxacalcitol (22-Oxacalcitriol) is a ligand of VDR-like receptors and a non-serum calcium vitamin D3 analogue. Maxacalcitol inhibits parathyroid hormone (PTH) mRNA expression in vitro and in vivo.
Targets(IC50)	Vitamin
In vitro	Maxacalcitol inhibits parathyroid hormone (PTH) mRNA expression in vitro and in vivo. Maxacalcitol inhibits tumor growth of osteosarcoma in vitro in combination with all-trans retinoic acid. Maxacalcitol shows similar effects to calcitriol in osteoblast-like cells.

## Solubility Information

Solubility	DMSO: 100 mg/mL (238.89 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (7.88 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

### Preparing Stock Solutions

---

	1mg	5mg	10mg
1 mM	2.3889 mL	11.9443 mL	23.8886 mL
5 mM	0.4778 mL	2.3889 mL	4.7777 mL
10 mM	0.2389 mL	1.1944 mL	2.3889 mL
50 mM	0.0478 mL	0.2389 mL	0.4778 mL

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Karashima T, et al. Successful Treatment of Bowen's Disease with Topical Maxacalcitol. *Acta Derm Venereol.* 2012 Jan 26.

Monier-Faugere, et al. 22-Oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure. *Kidney Int.* (1999)55 821.

Inoue K, et al. Maxacalcitol ameliorates tubulointerstitial fibrosis in obstructed kidneys by recruiting PPM1A/VDR complex to pSmad3. *Lab Invest.* 2012 Aug 27.

Barroga, et al. Inhibitory effects of 22-oxa-calcitriol and all-trans retinoic acid on the growth of a canine osteosarcoma derived cell-line in vivo and its pulmonary metastasis in vivo. *Res.Vet.Sci.* (2000)68 79.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481